Assessing the effectiveness of pharmacy-based adherence interventions on antiretroviral adherence in persons with HIV

AIDS Patient Care and STDs

Volumn 25, Issue 4, 2011, Pages 221-228

  Henderson, Kevin C ^a   Hindman, Jason ^b   Johnson, Steven C ^c   Valuck, Robert J ^a   Kiser, Jennifer J ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO HOSPITAL   (United States)

^c UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ATAZANAVIR PLUS RITONAVIR; EFAVIRENZ; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ETRAVIRINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; RALTEGRAVIR;

ADULT; AGED; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; FEMALE; HEALTH PROGRAM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; PATIENT COMPLIANCE; PATIENT COUNSELING; PATIENT REFERRAL; PHARMACIST; VIRUS LOAD;

ADOLESCENT; ADULT; AGED; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; DRUG MONITORING; DRUG PRESCRIPTIONS; FEMALE; HIV INFECTIONS; HOSPITALS, UNIVERSITY; HUMANS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PHARMACY SERVICE, HOSPITAL; PROSPECTIVE STUDIES; REFERRAL AND CONSULTATION; SEX DISTRIBUTION; YOUNG ADULT;

EID: 79953810807     PISSN: 10872914     EISSN: None     Source Type: Journal    
DOI: 10.1089/apc.2010.0324     Document Type: Article

References (37)

1. Kitahata MM, Reed SD, Dillingham PW, et al. Pharmacy-based assessment of adherence to HAART predicts virologic and immunologic treatment response and clinical progression to AIDS and death. Int J STD AIDS 2004;15:803-810. (Pubitemid 40018704)
2. Golin CE, Liu H, Hays RD, et al. A prospective study of predictors of adherence to combination antiretroviral medication. J Gen Intern Med 2002;17:756-765. (Pubitemid 35286241)
3. Atkinson MJ, Petrozzino JJ. An evidence-based review of treatment-related determinants of patients' nonadherence to HIV medications. AIDS Patient Care and STDs 2009;23:903-914.
4. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000;133:21-30. (Pubitemid 30432540)
5. Arnsten JH, Demas PA, Grant RW, et al. Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV-infected drug users. J Gen Intern Med 2002;17:377-381. (Pubitemid 34626108)
6. Bangsberg DR, Hecht FM, Charlebois ED, et al. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS 2000;14:357-366.
7. Maggiolo F, Ravasio L, Ripamonti D, et al. Similar adherence rates favor different virologic outcomes for patients treated with nonnucleoside analogues or protease inhibitors. Clin Infect Dis 2005;40:158-163. (Pubitemid 40053474)
8. Gulick RM. Adherence to antiretroviral therapy: How much is enough? Clin Infect Dis 2006;43:942-944.
9. Gross R, Yip B, Wood E, et al. Boosted protease inhibitors are more forgiving of suboptimal adherence than non-boosted protease inhibitors or nonucleoside reverse transcriptase inhibitors [Abstract 533]. Denver, CO: 13th Conference on Retroviruses and Opportunistic Infections, February 5-8, 2006.
10. Shuter J, Sarlo JA, Kanmaz TJ, Rode RA, Zingman BS. HIV-infected patients receiving lopinavir/ritonavir-based antiretroviral therapy achieve high rates of virologic suppression despite adherence rates less than 95%. J Acquir Immune Defic Syndr 2007;45:4-8. (Pubitemid 46684437)
11. McKinnel JA, Willig JH, Westfall AO, et al. Antiretroviral prescribing patterns in treatment-naïve patients in the United States. AIDS Patient Care STDs 2010;24:79-85
12. Shuter J. Forgiveness of non-adherence to HIV-1 antiretroviral therapy. J Antimicrob Chemother 2008;61:769-773. (Pubitemid 351426058)
13. Bisson GP, Rowh A, Weinstein R, et al. Antiretroviral failure despite high levels of adherence: Discordant adherence-response relationship in Botswana. J Acquir Immune Defic Syndr 2008;49:107-110.
14. Bangsberg DR. Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression. Clin Infect Dis 2006;43:939-941. (Pubitemid 44435526)
15. Lima VD, Harrigan R, Murray M, et al. Differential impact of adherence on long-term treatment response among naive HIV-infected individuals. AIDS 2008;22:2371-2380.
16. Simoni JM, Kurth AE, Pearson CR, Pantalone DW, Merrill JO, Frick PA. Self-report measures of antiretroviral therapy adherence: A review with recommendations for HIV research and clinical management. AIDS Behav 2006;10:227-245.
17. Nieuwkerk PT, Oort FJ. Self-reported adherence to antiretroviral therapy for HIV-1 infection and virologic treatment response: A meta-analysis. J Acquir Immune Defic Syndr 2005;38:445-448. (Pubitemid 40381555)
18. Liechty CA, Alexander CS, Harrigan PR, et al. Are untimed antiretroviral drug levels useful predictors of adherence behavior? AIDS 2004;18:127-129.
19. Wood E, Hogg RS, Yip B, Harrigan PR, O'Shaughnessy MV, Montaner JS. Effect of medication adherence on survival of HIV-infected adults who start highly active antiretroviral therapy when the CD4+ cell count is 0.200 to 0.350×10(9) cells/L. Ann Intern Med. 2003;139:810-816.
20. Sclar DA, Chin A, Skaer TL, Okamoto MP, Nakahiro RK, Gill MA. Effect of health education in promoting prescription refill compliance among patients with hypertension. Clin Ther 1991;13:489-495.
21. Yang Y, Thumula V, Pace PF, Banahan BF, 3rd, Wilkin NE, Lobb WB. Nonadherence to angiotensinconverting enzyme inhibitors and/or angiotensin II receptor blockers among high-risk patients with diabetes in Medicare Part D programs. J Am Pharm Assoc 2003;50:527-531.
22. Cambiano V, Lampe FC, Rodger AJ, et al. Use of a prescription-based measure of antiretroviral therapy adherence to predict viral rebound in HIV-infected individuals with viral suppression. HIV Med 2010;11:216-224.
23. Mannheimer SB, Morse E, Matts JP, et al. Sustained benefit from a long-term antiretroviral adherence intervention. Results of a large randomized clinical trial. J Acquir Immune Defic Syndr 2006;43(Suppl 1):S41-47.
24. Guerrault MN, Leclerc C, Langevin S, Merian-Brosse L, Brossard D, Welker Y. [Study of the usefulness of pharmacist consultations for patients on antiretroviral regimens]. Presse Med 2005;34:1563-1570.
25. Cantwell-McNelis K, James CW. Role of clinical pharmacists in outpatient HIV clinics. Am J Health Syst Pharm 2002;59:447-452. (Pubitemid 34208609)
26. Improving the prevention and treatment of HIV/AIDS through pharmacist interventions. In: Gal D, ed. The International Network for Pharmacists on HIV/AIDS: International Pharmaceutical Federation (FIP), 2004.
27. Knobel H, Carmona A, Lopez JL, et al. [Adherence to very active antiretroviral treatment: Impact of individualized assessment]. Enferm Infecc Microbiol Clin 1999;17:78-81.
28. McPherson-Baker S, Malow RM, Penedo F, Jones DL, Schneiderman N, Klimas NG. Enhancing adherence to combination antiretroviral therapy in non-adherent HIV-positive men. AIDS Care 2000;12:399-404.
29. Simoni JM, Frick PA, Pantalone DW, Turner BJ. Antiretroviral adherence interventions: A review of current literature and ongoing studies. Top HIV Med 2003;11:185-198.
30. VAMC. Pharmacist Counseling, use of compliance tool: Does it improve outcomes in an HIV population? Formulary 1998;33:1144.
31. Atkinson MJ, Petrozzino JJ. An evidence-based review of treatment-related determinants of patients' nonadherence to HIV medications. AIDS Patient Care STDs 2009;23:903-914.
32. Hirsch JD, Rosenquist A, Best BM, Miller TA, Gilmer TP. Evaluation of the first year of a pilot program in community pharmacy: HIV/AIDS medication therapy management for Medi-Cal beneficiaries. J Manag Care Pharm 2009;15:32-41.
33. Rueda S, Park-Wyllie LY, Bayoumi A, et al. Patient support and education for promoting adherence to highly active antiretroviral therapy for HIV/AIDS. The Cochrane Database Syst Rev 2006;3:CD001442.
34. Hugen PW, Burger DM, Koopmans PP, et al. Saquinavir soft-gel capsules (Fortovase) give lower exposure than expected, even after a high-fat breakfast. Pharm World Sci 2002;24:83-86. (Pubitemid 34754760)
35. Pellegrin I, Breilh D, Montestruc F, et al. Virologic response to nelfinavir-based regimens: Pharmacokinetics and drug resistance mutations (VIRAPHAR study). AIDS 2002;16:1331-1340. (Pubitemid 34722064)
36. Zhou XJ, Havlir DV, Richman DD, et al. Plasma population pharmacokinetics and penetration into cerebrospinal fluid of indinavir in combination with zidovudine and lamivudine in HIV-1-infected patients. AIDS 2000;14:2869-2876. (Pubitemid 32042750)
37. Ma A, Chen DM, Chau FM, Saberi P. Improving adherence and clinical outcomes through an HIV pharmacist's interventions. AIDS Care 2010:1-6.